Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PRNP | P04156 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5074576 | 0.92 | CDK1 (0.49) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| SCHEMBL3454549 | 0.85 | KCNH2 (0.60) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| SCHEMBL3454269 | 0.85 | CHRM2 (0.43) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| SCHEMBL1695274 | 0.83 | KDM4E (0.43) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| SCHEMBL1695271 | 0.81 | HRH3 (0.60) | SIGMAR1HRH3 | |
| Phosphoric Acid SCHEMBL5071916 | 0.79 | KDM4E (0.64) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| SCHEMBL6433202 | 0.78 | CDK1 (0.50) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| SCHEMBL1695386 | 0.78 | KDM4E (0.61) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| SCHEMBL3229048 | 0.77 | CDK1 (0.66) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| SCHEMBL1695273 | 0.77 | CDK1 (0.47) | CHRM2CHRM4CHRM5ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102297-A1 | ANTIBODY OLIGONUCLEOTIDE CONJUGATES FOR TREATING DISEASE | Fulcrum Therapeutics, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4126066-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | Avidity Biosciences, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-4121063-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | Avidity Biosciences, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-3898693-A1 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF | Avidity Biosciences, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| US-20210299266-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2021-09-30 | — | — | US | disclosed |
| WO-2021195469-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | AVIDITY BIOSCIENCES, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021188390-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| EP-3735252-A2 | HETERODUPLEX NUCLEIC ACID MOLECULES AND USES THEREOF | Avidity Biosciences, Inc. (US) | 2020-11-11 | — | — | EP | disclosed |
| WO-2020132584-A1 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF | AVIDITY BIOSCIENCES, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2019136180-A2 | HETERODUPLEX NUCLEIC ACID MOLECULES AND USES THEREOF | AVIDITY BIOSCIENCES LLC (US) | 2019-07-11 | — | — | WO | disclosed |
| EP-2585113-A1 | OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES | DNA Therapeutics (FR) | 2013-05-01 | — | — | EP | disclosed |
| WO-2012163814-A1 | CANCER TREATMENT BY COMBINING DNA MOLECULES MIMICKING DOUBLE STRAND BREAKS WITH HYPERTHERMIA | INSTITUT CURIE (FR) | 2012-12-06 | — | — | WO | disclosed |
| WO-2011161075-A1 | OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES | DNA THERAPEUTICS (FR) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299266-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | TNNC1, PYGM, MYOF | CHRM2 2268/4885CHRM4 3113/4885CHRM5 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.